Carregant...
Recent Findings in the Posttranslational Modifications of PD-L1
Immune checkpoint therapy, such as the reactivation of T-cell activity by targeting programmed cell death 1 (PD-1) and its ligand PD-L1 (also called B7-H1 and CD274) has been found pivotal in changing the historically dim prognoses of malignant tumors by causing durable objective responses. However,...
Guardat en:
| Publicat a: | J Oncol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Hindawi
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7199566/ https://ncbi.nlm.nih.gov/pubmed/32377193 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/5497015 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|